A5042127830- Cutaneous Melanoma Detection and Management
- Breast Cancer Treatment Studies
- CAR-T cell therapy research
- Immunotherapy and Immune Responses
- Nonmelanoma Skin Cancer Studies
- Breast Lesions and Carcinomas
- Melanoma and MAPK Pathways
- Breast Implant and Reconstruction
- Cancer Immunotherapy and Biomarkers
- Virus-based gene therapy research
- Cancer Genomics and Diagnostics
- Cell Image Analysis Techniques
- Cancer Cells and Metastasis
- Cutaneous lymphoproliferative disorders research
- Optical Coherence Tomography Applications
- AI in cancer detection
- Cancer Diagnosis and Treatment
- vaccines and immunoinformatics approaches
- T-cell and B-cell Immunology
- Allergic Rhinitis and Sensitization
- Monoclonal and Polyclonal Antibodies Research
- BRCA gene mutations in cancer
- Cancer Treatment and Pharmacology
- Cancer and Skin Lesions
- Reconstructive Surgery and Microvascular Techniques
The University of Texas MD Anderson Cancer Center
2016-2025
University of Zurich
2023
Yale University
2023
Huntsman Cancer Institute
2009-2021
University of Utah
2009-2021
University of Iowa Hospitals and Clinics
2017
Roswell Park Comprehensive Cancer Center
2006-2017
Scripps MD Anderson Cancer Center
2017
University of North Carolina at Chapel Hill
2017
Society of Surgical Oncology
2006-2016
To revise the staging system for cutaneous melanoma on basis of data from an expanded American Joint Committee Cancer (AJCC) Melanoma Staging Database.The recommendations were made a multivariate analysis 30,946 patients with stages I, II, and III 7,972 stage IV to clarify TNM classifications grouping criteria.Findings new definitions include following: (1) in localized melanoma, tumor thickness, mitotic rate (histologically defined as mitoses/mm(2)), ulceration most dominant prognostic...
PURPOSE: The American Joint Committee on Cancer (AJCC) recently proposed major revisions of the tumor-node-metastases (TNM) categories and stage groupings for cutaneous melanoma. Thirteen cancer centers cooperative groups contributed staging survival data from a total 30,450 melanoma patients their databases in order to validate this proposal. PATIENTS AND METHODS: There were 17,600 with complete clinical, pathologic, follow-up information. Factors predicting melanoma-specific rates analyzed...
Talimogene laherparepvec (T-VEC) is a herpes simplex virus type 1-derived oncolytic immunotherapy designed to selectively replicate within tumors and produce granulocyte macrophage colony-stimulating factor (GM-CSF) enhance systemic antitumor immune responses. T-VEC was compared with GM-CSF in patients unresected stage IIIB IV melanoma randomized open-label phase III trial.Patients injectable that not surgically resectable were randomly assigned at two-to-one ratio intralesional or...
Answer questions and earn CME/CNE To update the melanoma staging system of American Joint Committee on Cancer (AJCC) a large database was assembled comprising >46,000 patients from 10 centers worldwide with stages I, II, III diagnosed since 1998. Based analyses this new database, existing seventh edition AJCC stage IV contemporary clinical trial data, Melanoma Expert Panel introduced several important changes to Tumor, Nodes, Metastasis (TNM) classification grouping criteria. Key in eighth...
PURPOSE: To assess patient and tumor characteristics associated with a complete pathologic response (pCR) in both the breast axillary lymph node specimens outcome of patients found to have pCR after neoadjuvant chemotherapy for locally advanced cancer (LABC). PATIENTS AND METHODS: Three hundred seventy-two LABC received treatment two prospective trials using four cycles doxorubicin-containing chemotherapy. Patients had total mastectomy dissection or segmental followed by more additional then...
Objective The aim of this study was to determine the order melanoma nodal metastases. Summary Background Data Most solid tumors are thought demonstrate a random metastatic pattern. incidence skip metastases precluded use sampling procedures first station basins achieve adequate pathological staging. Malignant may be different from other malignancies in that cutaneous lymphatic flow is better defined and can mapped accurately. concept an orderly progression radically than what occur natural...
To determine the patterns of recurrence and causes regional nodal basin failure in stage I or II melanoma patients who had a histologically negative sentinel lymph node (SLN) whose basins were not dissected following lymphatic mapping SLN biopsy.The records 344 with primary cutaneous underwent biopsy between 1991 1995 at The University Texas M.D. Anderson Cancer Center reviewed. Of 322 successful procedures, 270 SLNs; mapped observed without further surgical intervention 243 these patients....
Gut bacteria modulate the response to immune checkpoint blockade (ICB) treatment in cancer, but effect of diet and supplements on this interaction is not well studied. We assessed fecal microbiota profiles, dietary habits, commercially available probiotic supplement use melanoma patients performed parallel preclinical studies. Higher fiber was associated with significantly improved progression-free survival 128 ICB, most pronounced benefit observed sufficient intake no use. Findings were...
Purpose We evaluated the combination of talimogene laherparepvec plus ipilimumab versus alone in patients with advanced melanoma a phase II study. To our knowledge, this was first randomized trial to evaluate addition an oncolytic virus checkpoint inhibitor. Methods Patients unresectable stages IIIB IV melanoma, no more than one prior therapy if BRAF wild-type, two therapies mutant, measurable/injectable disease, and without symptomatic autoimmunity or clinically significant...
Background The sentinel lymph node (SLN), the first draining primary tumor site, has been shown to reflect histologic features of remainder lymphatic basin in patients with melanoma. Intraoperative localization SLN, proposed by Morton and colleagues, accomplished use a vital blue dye mapping technique. Technical difficulties resulting unsuccessful explorations have occurred up 20% dissections. Objectives authors aimed define SLN using gamma detection probe determine whether intraoperative...
Whether pembrolizumab given both before surgery (neoadjuvant therapy) and after (adjuvant therapy), as compared with adjuvant therapy alone, would increase event-free survival among patients resectable stage III or IV melanoma is unknown.In a phase 2 trial, we randomly assigned clinically detectable, measurable IIIB to IVC that was amenable surgical resection three doses of neoadjuvant pembrolizumab, surgery, 15 (neoadjuvant-adjuvant group) followed by (200 mg intravenously every 3 weeks for...
The Melanoma Staging Committee of the AJCC has proposed major revisions melanoma TNM and stage grouping criteria. committee members represent most cooperative groups cancer centers worldwide with a special interest in melanoma; also collectively had clinical experience over 40,000 patients. new staging system better reflects independent prognostic factors that are used trials reporting outcomes various treatment modalities. Major include 1) thickness ulceration, but not level invasion, to be...
To determine the survival rates and independent predictors of using a contemporary international cohort patients with stage III melanoma.
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Cutaneous melanoma have been significantly revised over the past few years response to emerging data on immune checkpoint inhibitor therapies and BRAF-targeted therapy. This article summarizes rationale supporting extensive changes recommendations systemic therapy as adjuvant treatment of resected disease unresectable or distant metastatic disease.
Purpose To determine patterns of local-regional recurrence (LRR) and ipsilateral breast tumor (IBTR) among patients treated with conservation therapy after neoadjuvant chemotherapy. Patients Methods Between 1987 2000, 340 cases cancer were chemotherapy followed by conservative surgery radiation therapy. Clinical stage at diagnosis (according to the 2003 American Joint Committee on Cancer system) was I in 4%, II 58%, III 38% patients. Only 4% had positive surgical margins. Results At a median...
Adoptive cell therapy (ACT) using autologous tumor-infiltrating lymphocytes (TIL) is a promising treatment for metastatic melanoma unresponsive to conventional therapies. We report here on the results of an ongoing phase II clinical trial testing efficacy ACT TIL in patients with and association specific patient characteristics phenotypic attributes infused response.
Melanoma incidence continues to increase in whites, but little is known about melanoma minority populations. Surveillance, Epidemiology, and End Results (SEER) data were used examine the incidence, manifestations, survival patients with respect race/ethnicity.A SEER search (1992-2002) for primary invasive cutaneous cases identified 48 143 932 Hispanics, 394 Asian/Pacific islanders, 251 African Americans, 52 American Indians. Multivariate analyses performed evaluate relationship between...
Purpose The aim of this study was to assess the independent prognostic value primary tumor mitotic rate compared with other clinical and pathologic features stages I II melanoma. Methods From American Joint Committee on Cancer (AJCC) melanoma staging database, information extracted for 13,296 patients disease who had data available. Results Survival times declined as increased. Ten-year survival ranged from 93% whose tumors 0 mitosis/mm 2 48% those ≥ 20/mm (P < .001). Mean number...
Sentinel lymph node (SLN) surgery is widely used for nodal staging in early-stage breast cancer. This study was performed to evaluate the accuracy of SLN patients undergoing neoadjuvant chemotherapy versus first.Controversy exists regarding timing planned chemotherapy. Proponents after prefer a single surgical procedure with potential fewer axillary dissections. Opponents cite early studies low identification rates and high false-negative chemotherapy.A total 3746 clinically negative T1-T3...
This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Melanoma focuses on adjuvant therapy and treatment of in-transit disease, because substantial changes were made to recommendations 2016 update. Depending stage options now include biochemotherapy high-dose ipilimumab. Treatment disease intralesional injection with talimogene laherparepvec (T-VEC), a new immunotherapy. These additions prompted re-assessment data supporting older recommended resulting...
Over the past few years, NCCN Guidelines for Melanoma: Cutaneous have been expanded to include pathways treatment of microscopic satellitosis (added in v2.2020), and following Principles sections: Molecular Testing v2.2019), Systemic Therapy Considerations Brain Metastases Management v3.2020). The v1.2021 update included additional modifications these sections notable revisions of: Pathology, Surgical Margins Wide Excision Primary Melanoma, Sentinel Lymph Node Biopsy, Completion/Therapeutic...